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Available online 10 March 2016Pharmaceuticals are not currently tested for transgenerational and epigenetic side effects. The use of vertebrates
as preclinical researchmodels is limited by their long generation times, low numbers of progeny and ethical con-
cerns. In contrast, invertebrates such as insects breed rapidly, produce many offspring and are more ethically ac-
ceptable, allowing them to be used for high-throughput screening. Here, we established Tribolium castaneum as a
model to screen for the effect of drugs on complex ﬁtness parameters and the expression of epigenetic regulatory
genes. We tested diets supplemented with the psychoactive drug valproic acid (VPA), which is a histone
deacetylase inhibitor, or the antioxidant curcumin, which is a histone acetyltransferase inhibitor. We found
that VPA delayed development, reduced longevity, and increased female body weight compared to a control
diet. Fertility and fecundity declined and the expression of epigenetic regulatory genes was induced in the un-
treated F1 generation. In contrast, curcumin did not affect development or body weight, but it increased longev-
ity, caused a signiﬁcant reduction in fertility, and induced the expression of epigenetic regulatory genesmostly in
the treated F0 generation. VPA and curcumin administered to vertebrate models have similar effects to those we
observed in T. castaneum, conﬁrming that this beetle is potentially useful as an alternativemodel to screen for the
epigenetic effect of drugs. T. castaneum also provides a valuable early warning system for transgenerational
epigenetic risk factors that are difﬁcult to detect in mammals.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Valproic acid1. Introduction
Environmental effectors such as nutrients and pharmaceuticals may
trigger unanticipated epigenetic effects. They have the ability to regu-
late gene expression, leading to heritable changes in DNA structure me-
diated by DNA methyltransferases, histone acetyltransferases (HATs),
histone deacetylases (HDACs), and other histone-modifying enzymes
(Lötsch et al., 2013). Research in the ﬁeld of drug development is there-
fore turning to the analysis of potential epigenetic side effects, particu-
larly those that may be transferable to the next generation (Csoka and
Szyf, 2009; Skinner et al., 2010). Commonly-prescribed drugs are now
known to affect the etiology of many diseases including diabetes and
cancer (Mukherjee et al., 2015), and it is becoming clear that suchcetyltransferase; HDAC, histone
pG binding domain protein;Mt,
; Sap, Sin3A-associated protein;
Sir, sirtuin; SIRT, sirtuin; VPA,
logy, Heinrich-Buff-Ring 26-32,
.de (A. Vilcinskas).
. This is an open access article undereffects could be passed to the next generation via epigenetic mecha-
nisms (Whitelaw and Whitelaw, 2008). Preclinical studies usually re-
quire tests on at least two non-human species, typically mice and
larger mammals. However, vertebrate models have many limitations,
including their long generation times, low fecundity and the expense
of housing large numbers of animals. The use of vertebrates for drug re-
search also raises ethical concerns, and alternatives to reduce, reﬁne and
replace vertebrates (3Rs) are urgently required (Wilson-Sanders,
2011). Insects such as the model beetle Tribolium castaneum have
short generation intervals, high fecundity and can be reared inexpen-
sively in large numbers. They can be used to determine
transgenerational effects and for high-throughput drug screening as-
says with few ethical limitations (Knorr et al., 2013; Mukherjee et al.,
2015; Schmitt-Engel et al., 2015; Ulrich et al., 2015).
We investigated the use of T. castaneum, a global pest of stored food
products that has recently emerged as a model organism for functional
genomics and nutrition, to screen pharmaceutical products for epige-
netic risk factors (Denell, 2008; Grünwald et al., 2013a). T. castaneum
has been established as a screening platform for gene–food interactions
(Grünwald et al., 2013b; Grünwald et al., 2014), and as amodel for high-
throughput studies involving RNA interference (Knorr et al., 2013), andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Feliciello et al., 2013).
To evaluate the potential epigenetic side effects of drugs using this
model insect, we tested one known HDAC inhibitor and one known
HAT inhibitor. We chose valproic acid (VPA), a commonly-prescribed
psychoactive drug indicated for the treatment of epilepsy, migraine
and bipolar disorder (Lagace et al., 2004; Karragiannis et al., 2006),
which exerts epigenetic side effects by inhibiting histone deacetylation
(Göttlicher et al., 2001; Phiel et al., 2001; Rosenberg, 2007). VPA is asso-
ciated with common side effects such as weight gain (Dinesen et al.,
1984; Morrell et al., 2003; Ness-Abramof and Apovian, 2005; El-Khatib
et al., 2007; Verrotti et al., 2011) and teratogenic effects in early
pregnancy (Lindhout and Schmidt, 1986; Oakeshott and Hunt, 1989;
Phiel et al., 2001; Gurvich et al., 2004; Kimford and Loring, 2013). We
also selected curcumin, a powerful antioxidant and inhibitor of histone
acetylation best known as the yellow pigment in turmeric (Curcuma
longa) (Balasubramanyam et al., 2004). Curcumin has been used for
many centuries as a food additive and in Asian medicine to treat
wounds, inﬂammation and tumors (Sharma et al., 2005; Shen et al.,
2013). It is now used in the clinic to treat patients with pancreatic can-
cer (Aggarwal et al., 2003; Dhillon et al., 2008; Fu and Kurzrock, 2010).
Diets rich in antioxidants are associated with longevity (Suckow and
Suckow, 2006) and increases in lifespan have been reported in nema-
todes, fruit ﬂies and mice presented with such diets (Kitani et al., 2004;
Kitani et al., 2007; Shen et al., 2013; Soh et al., 2013; Chandrashekara,
et al., 2014). However, curcumin reduces fertility when administered
intravaginally, probably reﬂecting its concentration-dependent negative
impact on sperm motility (Naz, 2011). Curcumin does not appear to be
toxic in humans and other mammals even at high doses (Aggarwal
et al., 2003; Sharma et al., 2005; Ganiger et al., 2007).
Here we established a pre-screening system to test the effect of VPA
and curcumin on different complex ﬁtness parameters, i.e. the duration
of development, longevity, body weight and reproduction. We also
analyzed the expression of genes encoding epigenetic regulators in
the F0 and F1 generations to investigate the potential transgenerational
effects of these drugs.
2. Materials and methods
2.1. Insect maintenance
Wild-type T. castaneum strain San Bernardino was reared on
wholegrain ﬂour (basal medium) supplemented with 5% yeast powder
at 32 °C and 70% relative humidity in darkness (Knorr et al., 2009).
2.2. Drug supplements
The F0 generation was reared on basal medium containing 0.1 or 1%
(w/w) VPA (2-propylpentanoic acid) or curcumin (diferuloylmethane),
or 1% (w/w) diphenhydramine (DPH) as a control. All three substances
were obtained from Sigma-Aldrich (Taufkirchen, Germany). They were
ground with the basal ﬂour diet to form a ﬁne powder, which was
sieved to ensure homogenous distribution. The F1 generation was fed
on the non-supplemented basal diet. The oral dose of VPA in humans
is up to 10 mg/kg body weight with a maximum dose of 60 mg/kg per
day. The 0.1% and 1% VPA 116 supplements in the insect diets were
therefore equivalent to doses of 0.1 and 1 mg/kg body weight 117 in
humans.
2.3. Fitness parameters
The duration of developmentwas investigated by transferring fresh-
ly laid eggs (F0 generation) onto supplemented diets. Neonates were
transferred to 48-well plates and development was monitored daily
until the adult stage. Longevity was measured for all treatments in a
thermotolerance assayunder heat stress at 42 °C as described elsewhere(Grünwald et al., 2013b). Synchronized adult beetles were transferred
in groups of 25 to six-well plates with fresh basal or supplemented
diets, and deaths were recorded every 14 days or daily for the thermo-
tolerance assay.Weight differencesweremeasured in the F0 generation
in a pool of 10 adults per sex. Beetles were frozen at−18 °C for 24 h and
were then dried at 60 °C for 24 h to measure the dry weight.
To monitor reproduction, 10 adults per sex and treatment were
allowed to mate for one day, 5–7 days after eclosion, before transfer to
a fresh Petri dish where they laid eggs on supplemented white ﬂour
for 1 day. The eggs were separated from the ﬂour by sieving through a
300-μmmesh and were placed on the basal diet medium. Egg produc-
tion (fertility) and hatched larvae (fecundity) were counted daily until
day 6.
2.4. RNA isolation, reverse transcription and quantitative real-time PCR
Quantitative real-time PCR was carried out as previously described
(Knorr et al., 2015). Brieﬂy, RNA was isolated from shock-frozen ani-
mals (ﬁnal-instar larvae, n = 15, three replicates) using Direct-zol
RNA MiniPrep (Zymo Research, Irvine, California, USA). The quantity
and quality of the RNAwere determined using a NanoDrop spectropho-
tometer (Thermo Fisher Scientiﬁc, Waltham, Massachusetts, USA). We
prepared cDNA from 500 ng RNA using oligo(dT) primers and the
First Strand cDNA Synthesis Kit (Thermo Fisher Scientiﬁc) according
to the manufacturer's instructions. Gene-speciﬁc primers (Table 1)
were designed with Oligo Explorer v1.1.2 (Gene Link Inc., Hawthorne,
New York, USA) and purchased from Sigma-Aldrich. The ribosomal
protein gene RPS3 was used as an endogenous control (Toutges et al.,
2010). PCR was carried out on a StepOnePlus system using the Power
SYBR Green PCR Master Mix with 50 ng of cDNA per reaction (Applied
Biosystems,Waltham,Massachusetts, USA). Gene expressionwas calcu-
lated using the 2−ΔΔCT method described by Pfafﬂ (2001).
2.5. Statistics
Statistical analysis was carried out using SigmaPlot v11.0 (Systat
Software Inc., San Jose, California, USA). Statistical differences between
groups (parametric data) were determined by one-way analysis of
variance (ANOVA)with a signiﬁcance threshold of p b 0.05 and a subse-
quent Holm–Sidak test. When the normality test failed, ANOVA on-
Ranks with a subsequent Tukey's test was used instead. The longevity
data were analyzed using Kaplan–Meier survival curves and compared
using a log-rank test with a signiﬁcance threshold of p b 0.05. For each
experiment, comparisons to an untreated control group and DPH as an
additional control were included at the same time points. All experi-
ments were performed independently at least three times.
3. Results
3.1. Effects of VPA and curcumin on T. castaneumdevelopment and survival
The effects of VPA and curcumin on the development and survival of
T. castaneumwere tested by rearing the insects on a diet containing 0.1%
or 1% of each drug and comparing them with controls fed on a non-
supplemented diet. In the case of VPA, these doses represented 100-
fold and 10-fold lower doses per kg body weight than the standard
therapeutic dose in humans. The antihistamine DPH was used as an ad-
ditional control because no epigenetic side effects have been reported
for this compound. Accordingly we observed no differences in develop-
ment or survival between beetles fed on the non-supplemented diet
and the control diet supplemented with 1% DPH. The 0.1% VPA
diet also showed no signs of toxicity and had no impact on develop-
ment, but 1% VPA prolonged the larval stage by up to 3.62 ± 0.28 days
(Table S1, p b 0.001) and increased lethality during the larval stage by
35.56 ± 3.85% compared to the control diets (Table S2, p b 0.001).
Curcumin did not have any impact on larval development or survival.
Table 1
Gene-speciﬁc primer pairs for the analysis of epigenetic regulators by quantitative real-time RT-PCR.
Gene Acc. no. FOR seq REV seq
HDAC HDAC1 XM_961540.1 TTGTTCTGGGGATTTTGGAG TTGTGGAACGAGACTGTCATC
HDAC3 XM_964326.1 AGTCACGCCGCAGAACATC TCAAACAGCCCCCAGAAGAC
HDAC4 XM_962332.2 TGGTCAGAGGGAATGGATAC GCACTTTCAGCAGATTAGGC
HDAC11 XM_965563.1 CGAACTGGCACACTTTACCG TGGGGCGAGACTGATAAGC
SIRT4 XM_967874.1 GATTATCGCTCGGAAGATG CCCAACTTTGCCTACACTC
SIRT2 XM_967725.1 CCAAGACCTGCCTATAATCCC GACGAAGTGCCGATAACGAG
Sir2a XM_961975.2 GAAGCCGACGATGACAATG TCCAGAGAGGTCCGAAAGAC
Sir2b XM_963962.1 GCACTTTTTACACGGGACATTG CTCACATTCGGGGACTTCATC
SIRT6 XM_968003.1 ACGAGCATAAGGGTGTGTTAG AAGTCCAGACTCCATTAGGC
HDAC subunits Sin3A XM_969780.2 CGCTGAAAGAAGGAAGTGTG AGGTCGTCGTTGATTGCTG
Nap1 XM_965927.2 CCTCAAAGTCTTCCAAAACACG GACAAAAACTTCGGGCTGAAAG
sap30 XM_969026.1 ACATCTGCGACTTTCACAAG GTCATCCTCCGAATCCTTC
sap18 XM_968749.1 GTTTTTCGCTCGTTTTTCCC TGCTCCCTATTTCCCTCATTC
HAT KAT2 XM_964538.2 ATGGGTACGGCAATGAGTC CGGGAGTGTCAAGAGTTAGG
KAT3 XM_970561.2 CAAGCCAATCCGCAAGAAG ACAGCCACCGTTCGTTTTC
KAT5 XM_970317.2 CTGCCTCCGAACTTGTCAAC GCCCATCTTGCGAGTCTTC
KAT6 XM_965714.1 CGTCGCCAGAAATCTCATAC CTGGAAGCATCGTTATCGTC
KAT7 XM_965310.2 CGGAAGATGACGACAAACC TTAGTGGCGGCTTTAGGC
KAT8 XM_963338.1 CAAACCGTCGCAATCACAC TGTCCAGAGGCTGTTCTTCC
Methylases Mt1 NM_001134228.1 CTCGGATTTTGGTGACTTG ATCTTGGGGTAGTTTTGGG
Mt2 NM_001134229.1 GACGAAATTATCGGAATGGAC TGCTTGAGGATGTTTGTGTTC
MBD XM_964444.1 GCCGAAACAGTTGATTTGG CGTCTCCTCACTCACATTGG
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The impact of VPA and curcumin on the longevity of T. castaneum
was tested in a thermotolerance assay at 42 °C using the experimental
and control diets described above. The average lifespan of the control
animals under normal laboratory conditions at 32 °C was 247 ±
2.87 days but this was reduced to 158.08± 3.37 h at 42 °C. The thermo-
tolerance assay therefore allows longevity tests to be carried out more
rapidly. Similarly, the maximum lifespan of any beetle was 308 days atFig. 1. Longevity of T. castaneum fed on diets supplemented with VPA or curcumin. Kaplan–Me
and (B) 1%VPA signiﬁcantly reduced the lifespan under heat stress (42 °C) in the F0 and F1 gene
with (C) 0.1% curcumin and (D) 1% curcumin signiﬁcantly increased the lifespan under heat st
Holm–Sidak, ***p b 0.001). Synchronized adult beetles were used (n = 25, three replicates).32 °C but only 192 h at 42 °C. The diet supplemented with 1% DPH
showed no signiﬁcant inﬂuence on longevity, whereas both VPA and
curcumin affected the lifespan of the beetles as shown by the Kaplan–
Meier survival curves presented in Fig. 1. VPA signiﬁcantly reduced
the lifespan of the beetles regardless of the concentration. The diet con-
taining 0.1% VPA (Fig. 1A) reduced the average lifespan of the F0 beetles
by 13.7 ± 2.07% compared to the control diet (p b 0.001). Interestingly,
the effect persisted into the F1 generation, which was fed on a normal
diet— the lifespan was nevertheless reduced by 6.45 ± 2.0% comparedier survival curves showing that feeding beetles on diets supplemented with (A) 0.1% VPA
rations compared to the control groups. In contrast, feeding beetles on diets supplemented
ress (42 °C) in the F0 and F1 generations compared to the control groups (log-rank test —
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fects of VPA were greater at the higher dose of 1% (Fig. 1B). The lifespan
of the F0 beetles on the supplemented diet was reduced by 20.44 ±
1.29% compared to the control diet (p b 0.001). In the F1 generation,
longevity was reduced by 7.66 ± 2.58% compared to the control group
(p b 0.001). In contrast, curcumin signiﬁcantly extended the lifespan
of the beetles. The diet supplemented with 0.1% curcumin (Fig. 1C) in-
creased the average lifespan by 17.77±1% to 186.6±5.5 hwith amax-
imum lifespan of 240 h (p b 0.001) and the diet supplemented with 1%
curcumin increased the average lifespan by 8.48 ± 2.1% (Fig. 1D). The
effects of curcumin also persisted into the F1 generation despite the
beetles having no direct contact with the compound. The average
lifespan of the F1 beetles in the 0.1% curcumin group increased by
8.31 ± 1% compared to the control group (p b 0.05) and that of the F1
beetles in the 1% curcumin group increased by 6.69 ± 1.4% compared
to the control group (p b 0.05).
3.3. Effects of VPA and curcumin on reproduction
There were no differences in the rate of reproduction between bee-
tles fed on the non-supplemented diet and the DPH control diet. The
diet supplemented with 0.1% VPA did not affect reproduction in either
generation, but 1% VPA resulted in a lower number of eggs in the F0
and F1 generations (Fig. 2). When the quantity of eggs produced by
the control-group beetles was set to 100%, the 1% VPA diet caused a re-
duction to 73.52 ± 3.24% in the F0 generation and 79.24± 3.75% in the
F1 generation, indicating a slight but incomplete recovery (p b 0.001).
The fecundity of the beetles was also signiﬁcantly reduced at both
doses of VPA, and the effects persisted into the F1 generation. The hatch-
ing rate of F0 beetles fed on the diet containing 0.1% VPA fell by 26.83±
5.34% compared to the control diet, and in the F1 generation the hatch-
ing rate was still 13.0± 6.69% lower than the control group (p b 0.001).
The hatching rate of F0 beetles fed on the diet containing 1% VPA fell by
35.76 ± 4.73% and the hatching rate remained 25.19 ± 6.56% lower
than the control group in the F1 generation (p b 0.001). Curcumin also
reduced the fertility of the beetles at both concentrations (Table 2,
p b 0.001) but did not affect the number of eggs when only females
were treated (Table S3). Interestingly, the effect of curcumin in fertilityFig. 2. Reproduction of T. castaneum fed on diets supplemented with VPA. Feeding beetles
on a diet supplemented with 1% VPA reduced the number of eggs produced in the F0 and
F1 generations (Kruskal–Wallis one-way ANOVA on Ranks, Tukey's test, ***p b 0.001)
whereas a diet supplemented with 0.1% VPA had no impact. The number of hatched
eggs was reduced by both doses of VPA in both generations (one-way ANOVA, Holm–
Sidak, ***p b 0.001). The reproduction study was carried out with 5–7-day-old adult
beetles (n = 10 ♀ and 10♂, six replicates).did not persist into the F1 generation. Curcumin also had no effect on fe-
cundity in either generation.
3.4. Effects of VPA and curcumin on weight
The average weight of adult beetles was the same in cohorts fed on
the non-supplemented diet and the diet containing 1% DPH. Diets sup-
plemented with VPA increased the average weight of female beetles at
both test concentrations (Table 3). Diets containing 0.1% VPA increased
the average weight of female beetles by 22.2 ± 2.93% (p b 0.001),
whereas diets containing 1% VPA increased the average weight of
female beetles by 8.86 ± 1.68% (p b 0.001). Diets containing 0.1% VPA
increased the average weight of male beetles by 10.07 ± 1.59%
(p b 0.001), which is less than 50% of the weight gain experienced by
females. Diets containing 1% VPA reduced the average weight of male
beetles by 6.56 ± 2.05% (p b 0.01). Curcumin did not affect the average
weight of either males or females at either of the test concentrations.
3.5. Effects of VPA and curcumin on gene expression
Next we tested the impact of both drugs on the expression of epige-
netic regulatory genes. F0 last-instar larvaewere fed on a supplemented
ﬂour diet or the control diet supplemented with DPH, and the expres-
sion of 22 relevant genes was measured in the last-instar larvae of the
F0 and F1 generations by quantitative real-time RT-PCR. The test
genes represented four classes of epigenetic regulators: HDACs
(HDAC1, HDAC3, HDAC4, HDAC11, SIRT4, SIRT2, Sir2a, Sir2b and
SIRT6), HDAC subunits (Sin3A, Nap1, sap30 and sap18), HATs (KAT2,
KAT3, KAT5, KAT6, KAT7 and KAT8) and methylation enzymes (Mt1,
Mt2 and MBD). In the F0 generation, VPA had a small inhibitory effect
on the expression of class II HDAC4 at both tested concentrations
(Fig. 3A). In contrast, 1% VPA caused the signiﬁcant induction of 15
genes in the F1 generation (p b 0.001). The genes encoding SIRT4,
HDAC11, KAT8 and Mt1 were induced by more than 12-fold, whereas
those encoding Sir2a, Sin3a, KAT2 and Mt2 were induced by more
than 20-fold. The gene encoding subunit Nap1 was induced most
strongly among the genes we tested, with a 42-fold upregulation rela-
tive to the control. The lower dose of 0.1% VPA caused the signiﬁcant in-
duction of six tested genes in the F1 generation with the highest
induction of KAT5 with a 24-fold upregulation relative to the control.
However, this inductionwas not observed at the higher dose. Curcumin
at 0.1% caused the signiﬁcant induction of 18 genes in the F0 generation
(p b 0.001) whereas 1% curcumin caused the signiﬁcant induction of 10
genes (Fig. 3B). The expression proﬁle was similar at both doses of
curcumin, but in most cases the lower dose of 0.1% resulted in stronger
induction. The gene encoding KAT2 was induced most strongly among
the genes we tested, with a 61-fold upregulation triggered by 0.1%
curcumin and N45-fold induction triggered by 1% curcumin. Other key
results included the induction of Nap1 and Sin3a by more than 16-fold
and KAT5 by more than 20-fold. Most gene expression proﬁles in the
F1 generation were similar to the corresponding control levels, but the
genes encoding HDAC11 and KAT2 were still induced, although the lat-
ter only in offspring of the 0.1% curcumin treatment group. KAT6 was
slightly upregulated in the offspring of the 1% curcumin treatment
group and Sin3a was the only tested gene that was inhibited in the F1
generation (in the offspring of the 0.1% curcumin treatment group)
following the strong induction observed in the F0 beetles.
4. Discussion
Neither approved pharmaceuticals nor those still undergoing devel-
opment are currently tested for potential epigenetic side effects, includ-
ing transgenerational and heritable effects that manifest in subsequent
generations. The screening of drugs for transgenerational and epigenet-
ic side effects should be incorporated into safety assessments and this
has created a demand for suitable early warning systems (Csoka and
Table 2
Reproduction of T. castaneum fed on diets supplemented with curcumin. Beetles fed on diets supplemented with 0.1% or 1% curcuminwere compared to untreated controls— the exper-
imentwas carried outwith both sexes, only females or onlymales exposed to the supplemented diet (n= 10♀ and 10♂, six replicates; one-way ANOVA, Holm–Sidak). The differences in
egg number between the experimental and control groups are shown as percentages in brackets with the control groups set to 100% fertility.
No. of eggs (%)
Control 0.1% Curcumin 1% Curcumin
Both sexes 137.0 ± 7.7 (100 ± 7.69) 111.17 ± 7.3⁎⁎⁎ (81.22 ± 4.56) 107.83 ± 7.5⁎⁎⁎ (78.77 ± 4.65)
♀ 132.0 ± 8.0 (96.45 ± 5.12) 129.67 ± 7.3 (95.05 ± 9.62)
♂ 108.0 ± 4.9⁎⁎⁎ (78.98 ± 4.42) 108.5 ± 4.5⁎⁎⁎ (79.49 ± 6.98)
⁎⁎⁎ p b 0.001.
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tests will require a larger number of animals (mostly vertebrates),
more time and resources, and will also raise ethical concerns and in-
crease the amount of paperwork necessary to comply with the Animal
Welfare Act. Newmodels for preclinical research are therefore urgently
required (Whitelaw&Whitelaw, 2008; Mukherjee et al., 2015). Testing
pharmaceuticals in non-human species focusing on the assessment of
potential side effects is the main goal of preclinical development and a
large number of animals are often used prior to clinical trials.
We investigated the red ﬂour beetle T. castaneum as a potential
model pre-screening system to test the epigenetic risk factors associat-
ed with the antiepileptic drug VPA and the antioxidant curcumin. We
used this model to monitor different complex ﬁtness parameters and
compared beetles fed on diets containing different doses of VPA and
curcumin to those fed on non-supplemented diets or control diets con-
taining the epigenetically inactive drug DPH. Unlike vertebrate models,
insects have short generation intervals, high fecundity, and it is not
expensive to rear large numbers of individuals, making them suitable
for high-throughput screening (Knorr et al., 2013; Dönitz et al.,2015;
Schmitt-Engel et al., 2015). For these reasons, insects are already used
to test the potential toxicity of environmental chemicals (Lagadic and
Caquet, 1998), to study the epigenetic regulation of development
(Mukherjee et al., 2013) and to monitor aging-related processes
(Brandt and Vilcinskas, 2013). One of the great beneﬁts of T. castaneum
for pharmaceutical testing is its ingestion system, which allows pow-
dered drugs to bemixedwith a standard ﬂour-based diet, and advantage
that has already been exploited to screen for gene–food interactions
(Grünwald et al., 2013a). The complete T. castaneum genome sequence
is also available and this shows that T. castaneum shares more than 100
orthologous gene groups with humans, whereas the same gene
groups are absent in Drosophila melanogaster (Tribolium Genome
Sequencing Consortium, 2008). T. castaneum and mammals also
share conserved stress-response pathways (Altincicek et al., 2008;
Knorr et al., 2009; Knorr and Vilcinskas, 2011; Freitak et al., 2012).
These advantages make T. castaneum an ideal model for the pre-
screening of drugs before testing in vertebrate models and humans.
The administration of 1% VPA to T. castaneum resulted in greater lar-
val lethality and developmental delay compared to the control diets,
which concurs with the occasional delay of pubertal maturation in
children treated with VPA (Cook et al., 1992; Snyder and Badura,Table 3
Impact of VPA and curcumin on the average body weight of beetles in the F0 generation.
Weight differences between adult beetles fed on diets supplemented with VPA or
curcumin and those fed on control diets are presented as milligrams average weight per
10 adults (ﬁve replicates, one-way ANOVA, Holm–Sidak).
Treatment Concentration Weight per 10 adults [mg]
♀ ♂
Control 18.5 ± 0.41 18.54 ± 0.21⁎⁎⁎
VPA 0.1% 22.6 ± 0.31⁎⁎⁎ 20.52 ± 0.48⁎⁎⁎
1% 20.14 ± 0.58⁎⁎⁎ 17.68 ± 0.3
Curcumin 0.1% 19.16 ± 0.42 18.16 ± 0.63
1% 18.9 ± 0.66 17.44 ± 0.36
⁎⁎⁎ p b 0.001.1998; Novak et al., 1999). Animal tests have shown that the chronic
administration of VPA delays reproductive and skeletal maturation in
mice (Snyder & Badura, 1995), delays development in salamanders
and frogs (Oberemm and Kirschbaum, 1992; Pennati et al., 2001) and
even interrupts development in zebraﬁsh (Herrmann, 1993). In con-
trast, curcumin showed no evidence of toxicity or developmental
delay at the doses we tested, and even diets containing 10% curcumin
had no adverse effects (data not shown) concurring with the absence
of toxicity in mammals even at high doses. Indeed, clinical trials that
tested doses of up to 10 g/day showed no adverse effects (Aggarwal
et al., 2003; Sharma et al., 2005; Ganiger et al., 2007).
The longevity of T. castaneum under heat stress was reduced by the
administration of 0.1% VPA but the impact of 1% VPA was more severe,
reducing the lifespan by more than 30%. Even the untreated F1 genera-
tion had a shorter lifespan, which indicates a transgenerational impact
on beetle physiology triggered by the administration of VPA. In contrast,
the longevity of D. melanogaster and mice was not inﬂuenced by VPA
(Crochemore et al., 2009; Gayathri and Harini, 2012) and it even
extended the lifespan of the nematode Caenorhabditis elegans (Evason
et al., 2008). Diets supplemented with 0.1% or 1% curcumin had the op-
posite effect to VPA, extending the longevity of the beetles under heat
stress. Diets rich in antioxidants are thought to promote longevity
(Suckow and Suckow, 2006) as observed in D. melanogaster, C. elegans
and mice, indicating that an appropriate dose of curcumin could maxi-
mize the lifespan (Kitani et al., 2004; Suckow and Suckow, 2006;
Kitani et al., 2007; Liao et al., 2011; Shen et al., 2013; Chandrashekara
et al., 2014). We therefore tested diets containing higher doses of
curcumin (5% and 10%) but this did not increase the longevity any
further than the diet containing 1% curcumin (data not shown). The
lifespan was also extended in the untreated F1 generation. The
transgenerational effects of curcumin have also been reported in
D. melanogaster F1 and F2 generations, but it is not clear whether this
is due to epigenetic effects or the better health of the offspring
(Chandrashekara et al., 2014; Arking, 2015).
Theuse of antiepileptic drugs can reduce fertility and increase the in-
cidence of reproductive disorders (Löfgren et al., 2007). We found that
1% VPA reduced fertility in the F0 and F1 generations of T. castaneum
and that fecundity was reduced in beetles treatedwith either dose, con-
curring with a similar study showing reduced fecundity and fertility in
D. melanogaster treated with the same drug (Gayathri and Harini,
2016). Remarkably, the lower fecundity we observed in the F1 genera-
tion means that the impact of VPA is still prevalent in the F2 larvae. Ro-
dents treatedwith VPA show a reduction in epididymal weight, and it is
known that parental factors can contribute to fetal susceptibility, but no
changes in fertility have been reported (Faiella et al., 2000; Nishimura
et al., 2000). The potential for diverse teratogenic effects correlates
in vitro with the potency of HDAC inhibition (Göttlicher et al., 2016;
Phiel et al., 2001; Gurvich et al., 2004). These studies may therefore ex-
plain the substantial reduction of fecundity we observed in both gener-
ations at both doses of VPA. Fertility was also reduced after treatment
with curcumin but there were no differences to the number of hatched
larvae. Previous studies revealed no evidence for adverse reproductive
effects in D. melanogaster or rats (Bhavanishankar and Murthy, 1987;
Ganiger et al., 2007; Soh et al., 2013) whereas data from mice suggest
Fig. 3.Modulation of the expression of epigenetic regulator genes in T. castaneum fed on diets supplemented with VPA or curcumin. The expression level of different epigenetic regulator
genes was determined in last-instar larvae fed on diets supplemented with (A) VPA or (B) curcumin by quantitative real-time RT-PCR, and presented relative to the expression levels in
control larvae (one-way ANOVA, Holm–Sidak and Kruskal–Wallis, Tukey's test, ***p b 0.001). Data were normalized against the endogenous housekeeping gene Rps3 (n = 15, three
replicates).
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causes a signiﬁcant dose-dependent and exposure-dependent reduc-
tion in fertility and sperm motility (Naz, 2011). The latter was also
observed in humans (Rithaporn et al., 2003).
VPA often has side effects with an impact on body weight (Dinesen
et al., 1984; Morrell et al., 2003; Ness-Abramof and Apovian, 2005;
El-Khatib et al., 2007). Although the body weight of female beetles
was signiﬁcantly higher at both doses of VPA, theweight ofmale beetles
only increased in the 0.1% VPA diet group and declined in the 1% VPA
diet group. The mechanism of weight gain triggered by VPA is unclear.
In humans, signiﬁcant weight gain was observed in both genders, but
the effect was more severe in females (Morrell et al., 2003; El-Khatib
et al., 2007; Verrotti et al., 2011). In contrast, no differences in body
weight were observed in mice at any sampling age (Snyder and
Badura, 1995).
The administration of curcumin did not affect the body weight at
either concentration in either gender. Previous studies of curcumin as
a food additive have indicated its potential value as an anti-obesity
treatment. Curcumin interacts with adipocytes, macrophages andmus-
cle cells (Weisberg et al., 2008; Alappat and Awad, 2010; Bradford,
2013) and can increase the basal metabolic rate in mice fed on a high-
fat diet (Ejaz et al., 2009). Based on the data from both the VPA and
curcumin treatments, T. castaneum appears to be an ideal prescreening
model for weight-related side effects. There is increasing evidence that
pharmaceuticals such as VPA and curcumin are epigenetic modulators,
which modify the chemical structure of DNA without affecting its
base-pairing properties, but such potential epigenetic effects are not
yet assessed during drug development (Csoka & Szyf, 2009; Lötschet al., 2013). VPA is a well-known inhibitor of class I HDACs and can
thus affect the transcription of a large number of non-epigenetic regula-
tory genes (Phiel et al., 2001; Gurvich and Klein, 2002; Blaheta et al.,
2005). Curcumin is a HAT inhibitor, altering the expression of numerous
genes involved in signaling pathways, cell cycle control and transcrip-
tional regulation (Balasubramanyam et al., 2004; Shishodia, 2013). We
therefore screened the T. castaneum genome for genes related to epige-
netic mechanisms and tested 22 genes representing four different
classes of epigenetic regulator (HDACs and their subunits, HATs and
methylation enzymes). Both doses of VPA mildly inhibited the expres-
sion of class II HDACs (HDAC4) in the F0 generation but class I HDAC
was unaffected. The loss of HDAC activity is embryonic lethal in many
organisms (Mannervik and Levine, 1999; Phiel et al., 2001) which may
explain why VPA affects T. castaneum fecundity. Intriguingly, 1% VPA in-
duced all four classes of epigenetic regulator in the untreated F1 gener-
ation, conﬁrming that VPA interactswith the T. castaneum epigenome in
the subsequent generation. Curcumin slightly inhibited the expression
of HDAC4 in the F0 and F1 generations, a phenomenon that has been ob-
served inmedulloblastoma cells (Lee et al., 2011). Curcumin is known as
an inhibitor of p300/CREB-binding protein (KAT3) (Balasubramanyam
et al., 2004). TheKAT3 genewasmoderately induced in the F0 generation
(p b 0.05) and fell to control levels in the untreated F1 generation,
suggesting that transcriptional regulation may compensate when
the protein is inhibited. KAT2 activity is not affected by curcumin
(Balasubramanyam et al., 2004). However, the KAT2 gene was upreg-
ulated 61-fold by diets containing 0.1% curcumin and more than 45-
fold by diets containing 1% curcumin in the F0 generation, and this
effect persisted into the F1 generation where up to 4-fold induction
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transcriptional coactivators, in which case KAT2 may be able to
compensate for the inhibition of KAT3 activity. The modulation of
epigenetic regulatory genes by VPA and curcumin conﬁrmed the im-
portance of testing drugs for potential epigenetic transgenerational ef-
fects. VPA and curcumin each seem capable of modulating multiple
biological processes at low concentrations (Fu and Kurzrock, 2010).
5. Conclusions
T. castaneum showed a number of complex responses when fed on
diets supplemented with VPA or curcumin at two different doses, and
the effects were manifested over at least two generations. These results
indicate that both drugs have a longer-lasting effect than previous
studies have suggested, based onmodel vertebrates and human clinical
trials. The F1 generation and even the hatched F2 larvae showed
signiﬁcant evidence of transgenerational effects. The gene expression
proﬁles in T. castaneum revealed that VPA as an inhibitor of HDACs,
and curcumin as an inhibitor of HATs, each exert a signiﬁcant inﬂuence
on multiple epigenetic regulatory genes. In the case of VPA, the modu-
lated gene expression proﬁle was still apparent in the F1 generation,
whereas the effect of curcumin wasmost apparent in the F0 generation
exposed to the diet. Our novel pre-screening platform highlights the ad-
vantages of T. castaneum for the analysis of epigenetic effects. Drugs can
be added to the diet, and the high fecundity and short generation cycles
allow high-throughput screening for transgenerational effects that
would not be detected in vertebrate models. We therefore propose
T. castaneum as an ideal early warning system to indicate potential
epigenetic risk factors associated with drugs and their consequences
in subsequent generations.
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